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Experience Based Quality Control in IMRT Treatment Planning of High
Risk Post-Prostatectomy Prostate Cancer with RapidPlan
Abstract
Purpose: To develop a knowledge based planning (KBP) model with RapidPlan (Varian Medical Systems,
Palo Alto, USA) for the treatment of high risk post-prostatectomy prostate cancer. The model was trained on a
knowledge database of high quality treatment plans from the national clinical trial RTOG 0621, then tested as
a QA tool.
Methods: An initial dosimetric analysis was carried out to identify high quality plans from clinical trial RTOG
0621. Treatment plans for patients enrolled in the trial were scored according to the system used by the
Imaging and Radiation Oncology Core (IROC) of the National Clinical Trials Network (NCTN) of the NCI
to assess adherence to the trial protocol. Of the 80 plans enrolled in the trial 39 were chosen for the training
sample. Another subset of 8 plans, orthogonal to the training sample, was chosen for the validation sample to
ensure that the model accurately predicts dose volume histograms (DVHs) for all critical structures. The
validation plans were then re-optimized with the model in order to test its effectiveness as a tool for planning
QA. DVHs of the re-optimized plans were compared with those of the original clinical plans. Normal tissue
complication probabilities and tumor control probabilities were calculated with the Lyman-Kutcher-Burman
(LKB) model before and after re-optimization to determine the effect on patient outcome.
Results: The RapidPlan prostate model was shown to accurately predict estimated DVH bands for all plans in
the validation sample that matched the geometry of the training sample. Three treatment plans in the
validation sample were geometric outliers with respect to the training sample leading to inaccuracies in the
model predictions for the cone down phase of these treatment plans. All of the re-optimized plans showed
increased dose sparring to the bladder and rectum respectively without lose of target coverage. The average
reduction in NTCP was 0.34 ± 0.21 % for the bladder and 0.11 ± 0.25 % for the rectum with corresponding p-
values of 0.116 and 0.668. The average TCP for the prostate bed decreased slightly from 97.05 % to 96.54 %
with a p-value of 0.149. Due to limited statistics the changes reported in these numbers are not statistically
significant as indicated by the p-values. Although the average values are inconclusive the model was effectively
used to identify sub-optimal treatment plans which were improved through re-optimization with the model.
For treatment plan 0621c0027 the NTCP decreased from 0.35 % to 0.06 % for the bladder and from 0.10 % to
0.06 % for the rectum while the TCP increased from 96.78 % to 96.87 %.
Conclusions: The RapidPlan prostate model developed in this study is an effective tool for monitoring the
quality of IMRT treatment plans for high-risk post prostatectomy prostate cancer.
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Abstract
Purpose: To develop a knowledge based planning (KBP) model with RapidPlan (Varian Medical Systems,
Palo Alto, USA) for the treatment of high risk post-prostatectomy prostate cancer. The model was trained
on a knowledge database of high quality treatment plans from the national clinical trial RTOG 0621, then
tested as a QA tool.
Methods: An initial dosimetric analysis was carried out to identify high quality plans from clinical trial
RTOG 0621. Treatment plans for patients enrolled in the trial were scored according to the system used
by the Imaging and Radiation Oncology Core (IROC) of the National Clinical Trials Network (NCTN) of
the NCI to assess adherence to the trial protocol. Of the 80 plans enrolled in the trial 39 were chosen
for the training sample. Another subset of 8 plans, orthogonal to the training sample, was chosen for
the validation sample to ensure that the model accurately predicts dose volume histograms (DVHs) for
all critical structures. The validation plans were then re-optimized with the model in order to test its
effectiveness as a tool for planning QA. DVHs of the re-optimized plans were compared with those of
the original clinical plans. Normal tissue complication probabilities and tumor control probabilities were
calculated with the Lyman-Kutcher-Burman (LKB) model before and after re-optimization to determine
the effect on patient outcome.
Results: The RapidPlan prostate model was shown to accurately predict estimated DVH bands for all
plans in the validation sample that matched the geometry of the training sample. Three treatment plans
in the validation sample were geometric outliers with respect to the training sample leading to inaccuracies
in the model predictions for the cone down phase of these treatment plans. All of the re-optimized plans
showed increased dose sparring to the bladder and rectum respectively without lose of target coverage. The
average reduction in NTCP was 0.34 ± 0.21 % for the bladder and 0.11 ± 0.25 % for the rectum with
corresponding p-values of 0.116 and 0.668. The average TCP for the prostate bed decreased slightly from
97.05 % to 96.54 % with a p-value of 0.149. Due to limited statistics the changes reported in these numbers
are not statistically significant as indicated by the p-values. Although the average values are inconclusive
the model was effectively used to identify sub-optimal treatment plans which were improved through re-
optimization with the model. For treatment plan 0621c0027 the NTCP decreased from 0.35 % to 0.06 %
for the bladder and from 0.10 % to 0.06 % for the rectum while the TCP increased from 96.78 % to 96.87
%.
Conclusions: The RapidPlan prostate model developed in this study is an effective tool for monitoring
the quality of IMRT treatment plans for high-risk post prostatectomy prostate cancer.
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1 Introduction
Worldwide prostate cancer is the second most com-
mon cancer among men and the fifth most common
overall [1]. Radical prostatectomy has become the
standard of care in the treatment of prostate cancer
with an estimated 20 % of patients receiving adju-
vant radiation therapy (RT) for pT3 disease (extra-
capsular extension and/or seminal vesicle invasion)
and 16 % receiving salvage RT for positive surgical
margins. [2] Post-prostatectomy RT for either pT3
disease or positive surgical margins has been shown
to reduce the risk of recurrence in three randomized
trials: Southwest Oncology Group (SWOG), Euro-
pean Organization for Research and Treatment of
Cancer (EORTC) and Auckland Radiation Oncology
(ARO). [3, 4, 5]. Furthermore studies have shown
that compared with 3D Conformal Radiation Ther-
apy (3DCRT) Intensity Modulated Radiation Ther-
apy (IMRT) can achieve better target conformity
leading to increased sparing of nearby organs-at-risk
(OARs) such as the bladder, rectum and femoral head
as well as reduced GI/GU toxicity. [6, 7, 8]
RTOG 0621 is a phase II clinical trial that aimed
to assess whether the addition of androgen sup-
pression therapy (AST) and docetaxel to adjuvant
3DCRT/IMRT radiation therapy in the treatment
of high-risk post-prostatectomy prostate cancer im-
proves freedom from progression (FFP) defined as
a prostate specific antigen (PSA) < 0.4 ng/mL and
no clinical failure (loco-regional or distant failure) in
three years. The trial stipulates a prescription dose
of 66.6 Gy (±1.8 Gy) to the prostate bed and 50.4
Gy to the pelvic lymph nodes in 1.8 Gy fractions. It
opened in April 2008 with a target accrual of 76 pa-
tients and closed in September 2010 having accrued
80 patients.
Although IMRT offers clear clinical benefits to
3DCRT one disadvantage is that there is significant
variation in the quality of treatment plans across the
field [9, 10]. This is particularly evident when com-
paring treatment plans produced at University hos-
pitals and large research centers with those produced
at smaller community hospitals [11]. Plan quality
depends heavily on the knowledge and experience of
planners as well as the institutional resources avail-
able to them. The inverse planning process used in
IMRT planning can make it difficult for inexperienced
planners to know whether a plan is fully optimized or
whether it can be improved further by devoting more
time and effort to it. Combined with the need to
minimize planning time per patient, given limited re-
sources, this leads to significant differences in plan
quality across institutions. Studies have shown that
suboptimal IMRT plans are associated with increased
normal tissue complication risks [12]. A concerted ef-
fort must be made to reduce the variability in treat-
ment plans and to improve their overall quality.
Knowledge based planning (KBP) techniques have
been developed to predict dose volume histograms
and optimal dosimetric objectives for IMRT treat-
ment planning [13]. These techniques study the cor-
relations between patient anatomy, in particular the
position of OARs relative to the target, and dose dis-
tribution and use these correlations to predict the
optimal dose distribution for a patient given their
target-OAR geometry. Principal Component Analy-
sis (PCA) is used to characterize the salient features
of the patient anatomy and dose distribution and
Support Vector Regression (SVR) is used to model
their correlation. These mathematical tools are de-
scribed in detail in the context of adaptive IMRT
planning of prostate cancer in [14].
RapidPlan (Varian Medical Systems, Palo Alto,
USA) is a commercially available KBP tool that al-
lows users to build predictive models for particular
treatment sites and pathologies by training them on
a collection of high quality plans from previously
treated patients. These models can then provide a
guideline for treatment planners to better understand
the plan quality that is achievable on a case by case
basis.
There is good evidence that adherence to trial com-
pliance criteria is a strong indicator of high plan qual-
ity which is associated with increased survival in pa-
tients enrolled in national clinical trials [15]. This
suggests that treatment plans from patients enrolled
in national clinical trials, that adhere well with com-
pliance criteria, are a natural place to look for high
quality plans from which to train a RapidPlan model.
This paper presents the results of a prostate model
built with RapidPlan and trained on a collection of
high quality cases from RTOG 0621. The model was
validated and tested as a tool for planning QA on an
orthogonal set of plans from the same trial.
2 Theory
2.1 Knowledge Based Planning
The aim of KBP is to use a database of high quality
treatment plans to predict the optimal dose distribu-
tion for a given patient anatomy. These predictions
then provide a guideline for planners that indicate the
degree of OAR sparing that is achievable. The main
benefit of KBP is that it allows planners to more
easily distinguish plans that can be improved further
from those that are already fully optimized, which
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allows them to better manage their time. By incor-
porating KBP tools into routine treatment planning
radiation oncology departments can make the best
use of resources to treat more patients without sacri-
ficing plan quality.
This study makes use of a KBP tool, known as
RapidPlan, available in Eclipse treatment planning
system (TPS) version 13.6.5. RapidPlan is based on
the work of Zhu et al [14] which uses PCA to build
KBP models by identifying the most important fea-
tures of patient anatomy and dose distribution and
studying their correlations.
2.2 Principal Component Analysis
PCA is used to characterize high dimensional data
in reduced dimensions by extracting the most salient
features. This is particularly useful when studying
the correlation between two high dimensional data
sets. Despite the high dimensions of the data sets
their correlation is often dominated by a limited
number of important features. Thus the problem
can be simplified considerably by identifying these
features through PCA and describing their correla-
tion. In the context of IMRT treatment planning
the two data sets are the dose distribution and the
target/OAR geometry for a collection of treatment
plans. The dose distribution data consists of the
DVHs for each OAR. The target/OAR geometry
data consists of the target and OAR volumes and
the distance-to-target histograms (DTH) for each
OAR. The DTH shows the fractional volume of an
OAR within a certain distance of the PTV surface.
For voxels inside the PTV the distance is negative,
indicating overlap. An example DTH for a rectum is
shown in Fig. 1 [14]
Figure 1: Example distance-to-target histogram for
the rectum in a prostate cancer patient [14]. Ap-
proximately 10 % of the rectum overlaps with the
target.
Each DVH and DTH is sampled m times (m = 50
in the original work by Zhu et al [14]) producing an m
component vector called a feature point. These fea-
ture points populate an n dimensional feature space
for each OAR where n is the number of treatment
plans in the data set. The feature point correspond-
ing to the average curve (DVH or DTH) is identi-
fied and the origin of the coordinate system is shifted
there such that the components of each feature point
now represent deviations from their average value.
The feature points are then normalized such that the
standard deviation of each component about 0 is 1.
The m×m covariance matrix of the n feature points
in this shifted coordinate system is formed and diag-
onalized to find the m eigenvectors and eigenvalues.
The eigenvectors now define a new coordinate system
which is a rotation of the shifted coordinate system.
The components of the feature points in this rotated
system no longer represent the m sampled points of
the curve but some distinct features of the data which
are some combination of the sampled points. The
eigenvalues give the average deviation of these com-
ponents from their average. A subset of these com-
ponents with the largest deviations are identified as
the principle components (PCs) and their values are
the principle component scores (PCSs). PCSs are
specified for each PC (1st PC, 2nd PC, etc...) of the
geometric and dosimetric data of each OAR in each
treatment plan.
Once the PCs are identified for the dosimetric and
geometric data SVR is used to map their correla-
tions. The map can then be used to determine the
dosimetric PCSs from the geometric PCSs that are
derived from the geometric input which include the
target and OAR volumes and DTHs for each OAR.
The DVH for the patient can then be predicted from
the dosimetric PCSs by simply applying the inverse
rotation and translation to revert back to the original
feature space in which the components correspond to
the m sample points of the DVH.
2.3 RapidPlan
RapidPlan allows users to build KBP models for
specific disease sites by training from a database
of high quality plans. It applies PCA and SVR to
the training sample to develop a mapping between
geometric and dosimetric features which can be
used to produce estimated DVH (EDVH) bands for
patients with similar geometry. The bands represent
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one standard deviation variation around the model
predicted average DVH. Planners can then proceed
to optimize the treatment plan for the patient as in
conventional inverse planning but also making use of
the EDVH bands to understand the degree of OAR
sparing that can be expected.
RapidPlan includes a number of tools to visualize
the training results of a model. These include overlay
plots of the clinical DVHs and EDVH bands, residual
plots that show the actual PCS values against the
model predicted values and regression plots showing
the correlation between the leading dosimetric
PCS and the most important geometric regression
parameter which may be the leading geometric PCS,
another feature such as a the target or OAR volume
or some combination of these. It also displays the
goodness of fit parameters R2 and χ2.
It is important to ensure that the training sample
includes enough treatment plans for the full range
of geometries the model is intended for. If there are
geometric outliers in the training sample the model
will be overtrained for that specific geometry and
predict narrow EDVH bands based on the DVH
for that particular plan. Outliers should either be
removed from the training sample or more plans of
that geometry should be added so that the model is
no longer overtrained. RapidPlan calculates a range
of outlier statistics for each OAR in each plan in the
training sample to help the user identify potential
outliers. These include the crook’s distance, modified
z score, studentized residual and areal difference
in estimate. If any of these statistics exceed a
specific threshold value they are highlighted for
further investigation. It also displays geometric box
plots showing the distribution of various geometric
features of the training data including the geometric
PCSs.
3 Methods and Materials
3.1 Dosimetric Analysis of Clinical
Treatment Plans in RTOG 0621
The treatment plans submitted to RTOG 0621 were
analyzed to determine how well each plan adheres to
the compliance criteria specified in the trial protocol.
The Imaging and Radiation Oncology Core (IROC)
of the National Clinical Trials Network (NCTN) of
the NCI implements a scoring scheme to assess the
compliance of each plan in a trial. Under the scheme
a plan receives a score from 1 to 3 with 1 indicating
the most compliant plans, 2 indicating plans that are
less compliant but still acceptable and 3 indicating
plans that are a protocol violation. The RT compli-
ance criteria of a national clinical trial consist of a
set of constraints on dosimetric parameters for the
target and all relevant critical structures. Score 1
plans meet all constraints while score 2 plans show
a variation of one or more parameters with respect
to the constraint value within a range that is deemed
acceptable. Score 3 plans show a variation outside
of this acceptable range. The compliance criteria for
RTOG 0621 are shown in Table 1. Target 1 includes
the prostate bed and the pelvic lymph nodes (LNs)
and is taken to 50.4 Gy. Target 2 is the prostate bed
alone and is taken to 66.6 ± 1.8 Gy. The criteria
include constraints on V100% and dose heterogeneity
Dhet = (D2%-D98%)/DRx for each target to ensure
coverage and homogeneity and upper limits on V50Gy
and V66.6Gy for the Bladder and Rectum.
All plans submitted to RTOG 0621 were analyzed
by exporting the Dose Volume Histograms (DVHs)
from MIM (MIMsoftware Inc, Cleveland, OH 44122)
in the IROC analysis environment of the IROC/ACR
cloud and processing them with a MatLab [16] tool
which extracts dose-volume statistics. These statis-
tics were then compared with the constraints outlined
in the trial protocol to assign a score to each plan. A
summary of the results of this analysis including the
percentages of plans that pass each criteria are shown
in Table 3. These scores were then used to help select
plans for the knowledge database used to train the
model. Score 1 and 2 plans were selected for the ini-
tial training sample since evidence suggests a strong
correlation between overall survival and compliance
with the trial protocol [15].
3.2 Model Building and Validation
Of the 80 patients submitted to the trial 22 were
either 3DCRT plans or could not be used for other
reasons such as incomplete treatment or missing
data. Of the remaining 58 patients 47 have been
used in this study. The DICOM data (CT, RTStruct,
RTPlan and RTDose files) for these 47 treatment
plans were imported to Eclipse treatment planning
system (TPS) version 13.6.15. 39 score 1 and 2
plans were chosen for the training sample and the
remaining 8 were used for validation and testing the
model. The plans were submitted to the trial by
various institutions and so were planned for different
machines and with different TPSs. The trial protocol
specifies a prescription dose of DRx = 66.6/1.8 ±
1.8 Gy. Of the 47 treatment plans used in the study
27 have a prescription dose of 66.6 Gy, 9 have 64.8
Gy and 11 have 68.4 Gy. The protocol requires a
3
Table 1: Compliance criteria for RTOG 0621 national clinical trial. The criteria include constraints on the
targets and two organs-at-risk (OARs): the bladder minus the prostate bed and the rectum. Target volume
1 includes the prostate bed and pelvic lymph nodes and target volume 2 includes only the prostate bed.
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target coverage of V100% ≥ 95% with an allowed
variation of 5% for a minimum of V100% ≥ 90%. All
plans included in the model had target coverage at
or above 95%. Before adding them to the model
they were renormalized to 95% for consistency and
easy comparison. Scaling plans in this way has been
shown not to effect the quality of the model [17].
All patients in the trial were treated in two phases.
The initial phase covers target 1 with 45 Gy or 50.4
Gy (if PTV1 includes the remnants of the seminal
vesicles) and the cone down (CD) phase covers target
2 to 66.6 ± 1.8 Gy. These are referred to as PTV1
and PTV2 in the following. Since the treatment
plans were separated in this way separate RapidPlan
models were built for the initial and CD phases. The
models were trained and validated separately.
The models were initially trained on 39 score 1
and 2 clinical plans submitted to the trial. These
plans were then re-optimized in order to try to
achieve better sparing of the bladder-CTV2 and
rectum while maintaining target coverage at 95%
and minimizing Dhet within the target as much
as possible. This re-optimization was done using
the model as a guideline. The model was applied
to each plan to generate estimated DVH bands
and line objectives to aid in the re-optimization
process. Plans for which dose sparing of these
OARs was increased without violating the criteria
on target coverage and dose heterogeneity described
in Table 1 were judged to be an improvement. The
re-optimized plans were then added to the model
in place of the original clinical plans and the model
was re-trained. The new refined model was then
used to re-optimize plans in the training sample
further and the process was repeated until the plans
were optimized as much as possible. All plans
were re-optimized using Eclipse (13.6.15) with a
Clinac 23EX beam model and 400 MU/min dose rate.
3.3 Quality Assurance and Plan Opti-
mization
To test the results each model is applied separately
to the initial and boost phases of all the plans in
the validation/testing sample. A plan sum is then
made from the re-optimized initial and boost plans
and compared to the original plan sum. The clini-
cal and re-optimized treatment plans were studied to
determine whether re-optimization with RapidPlan
improved the quality of treatment in these cases.
3.3.1 Biological Analysis of Optimized Plans
A biological analysis was carried out in order to quan-
tify the effect of re-optimization in terms of patient
outcome. First the values of V50Gy and V66.6Gy were
compared before and after re-optimization. Con-
straints are placed on these dose volume parameters
for both the bladder-CTV2 and rectum in the com-
pliance criteria for this trial, shown in Table 1. They
also coincide with the range of parameters found to
be correlated with biological outcome for these OARs
by Emammi and Burman [18]. They found that the
probability of grade 2-3 late rectal and bladder toxi-
city is constrained by placing upper limits on V50Gy-
V75Gy and V65Gy-V80Gy for the rectum and bladder
respectively.
In addition to studying the effect of re-optimization
on these dose volume parameters the equivalent uni-
form dose (EUD), normal tissue complication proba-
bility (NTCP) and tumor control probability (TCP)
were calculated using the Lyman-Kutcher-Burman
(LKB) model. The EUD is defined as the uniform
dose which produces the same probability of a par-
ticular biological endpoint as a given inhomogeneous
dose distribution. In this study it is calculated with
the following equation
EUD =
(
ΣviD
a
i
)1/a
(1)
due to Niemierko [19], where a is a dimensionless
model parameter that depends on the tissue irradi-
ated. In the LKB model NTCP is defined in terms
of the error function as
NTCP =
1√
2pi
∫ t
−∞
e−t
2/2dx (2)
t =
EUD − TD50(v)
m× TD50
TD50(v) = TD50(1)/v
n
v = V/Vref where V is the volume irradiated and
Vref is a reference volume. When Vref is the total
volume v is the fraction of the structure irradiated.
Equ. 2 yields the characteristic sigmoid shape that
describes the biological response of tissue to radia-
tion.
This model contains four parameters which must
be determined from a fit to clinical data. They in-
clude Vref , TD50, m and n. TD50 is the tolerance
dose for a 50 % complication rate at 5 years after
treatment. m determines the slope of the sigmoid. n
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describes the volume dependence of TD50 and is the
reciprocal of the parameter a in equation 1. In this
work the NTCP is calculated with
NTCP =
1
1 +
(
TD50
EUD
)4γ50 (3)
This is an approximation of the integral definition
given in Equ. 2 which does not have a closed form
solution. γ50 is not another independent model pa-
rameter but rather a combination of the others. TCP
for the prostate bed is calculated with an equation
similar to Equ. 3 with TD50 replaced with TCD50
defined as the uniform dose to achieve 50 % local con-
trol after 5 years. The values of the model parameters
used in this study to calculate EUD, TCP and NTCP
are taken from a fit to the Emami data [20, 21] and
are summarized in Table 2. The biological endpoints
are symptomatic contraction and volume loss for the
bladder and severe proctitis/necrosis, stenosis/fistula
for the rectum.
In order to calculate EUD for a given dose dis-
tribution from these parameters the DVHs must be
converted to the biological equivalent dose (BED) of
the source data from which the parameters were de-
termined. This is done on a voxel-by-voxel basis by
first converting the cumulative DVH to the differen-
tial DVH and then calculating BED for each dose bin.
The fractionation for each bin is the dose divided by
the total number of fractions. The fractionation for
the Emami source data is 1.8 Gy/Fx. This BED cal-
culation requires the α/β parameters for each struc-
ture which are also given in Table 2
Table 2: LKB model parameters used to calculate
EUD, TCP and NTCP in this study. [20, 21]
4 Results and Discussion
The results of the initial dosimetric analysis of the
treatment plans in RTOG 0621 are shown in table 3.
The table shows the number of treatment plans that
receive a score of 1, 2 and 3 in the IROC scoring
scheme described in section 3.1 for each of the compli-
ance criteria stipulated in the trial protocol. Table 4
gives a summary of these results. It shows the num-
ber of plans that score 1, 2 and 3 for all constraints
on targets (CTV1, CTV2, PTV1 and PTV2) and or-
gans at risk (bladder-CTV2 and rectum). Each plan
is given an overall score for targets and OARs equal
to the lowest score (highest number) for any of the
target and OAR constraints. 43 of the 47 training
plans used in this study receive scores of 1 or 2 for all
structures meaning that they satisfy all compliance
criteria according to the protocol requirement ’per
protocol’ or they vary within an acceptable range of
the protocol requirement ’variation acceptable’. The
remaining 5 plans violate at least one of the compli-
ance criteria. 39 of the 43 score 1 and 2 plans were
chosen for the training sample from which to build
the RapidPlan model.
It was assumed that score 1 and 2 plans would pro-
vide the best starting point to build a sample of high
quality plans from which to build the model. How-
ever there is not a one-to-one correspondence between
the IROC score and the quality of a treatment plan.
Plan quality depends on the patient anatomy and
in particular the target and OAR geometry. Treat-
ment plans that receive an IROC score of 3 may vio-
late the compliance criteria despite being high quality
plans because the geometry makes planning particu-
larly difficult. It may be that these plans achieve the
best OAR sparing possible given the challenging ge-
ometry. Similarly a score 1 or 2 plan may not be a
high quality plan if the geometry makes it particu-
larly easy to meet the compliance criteria. Therefore
the plans chosen for the training sample must be fur-
ther optimized in order to ensure the strength of the
model. Starting with score 1 and 2 plans was merely
the most practical and efficient way of building the
training sample.
Table 4: Summary of the results of the preliminary
dosimetric analysis of the treatment plans in RTOG
0621 used in this study. A total of 47 treatment plans
from the trial were used in the study.
4.1 Model Optimization
Fig 2 shows an example DVH comparing one of the
original clinical treatment plans submitted to the
trial to the model re-optimized plan. This treat-
ment plan is included in the training sample and was
re-optimized in order to improve the quality of the
model. After re-optimization the clinical treatment
plan was replaced in the training sample by the re-
optimized plan and the model was retrained. This
process was repeated in a number of iterations in
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Table 3: Results of the preliminary dosimetric analysis of the treatment plans in RTOG 0621 used in this
study. The table shows the number of plans that score 1, 2 and 3 for each of the trial compliance criteria
shown in table 1. A total of 47 treatment plans from the trial were used in the study.
order to achieve the highest quality possible for the
treatment plans in the training sample. The full set
of DVHs for all re-optimized plans in the training
sample are shown in appendix A.
The plots show a significant improvement of OAR
sparing for both the rectum and bladder-CTV2 with-
out sacrificing target coverage. In general the re-
optimized plans do have increased dose heterogeneity
within the target with respect to the original clini-
cal plans submitted to the trial. This can lead to a
degradation in plan quality as it may reduce TCP
of the prostate bed. Clinically this must be weighed
against the benefit of the increase in dose sparing
to the bladder-CTV2 and rectum which will reduce
NTCP for these OARs. Ultimately the decision of
which treatment plan is of higher overall quality and
therefore should be delivered to the patient is made
by a physician on the basis of their clinical experience
and a range of considerations specific to the patient.
For the purposes of this study a moderate increase in
dose heterogeneity within the target was accepted if
it lead to significant increase in dose sparing to the
OARs.
Figure 2: Dose volume histogram (DVHs) showing a
comparison of the initial clinical treatment plan with
the treatment plan re-optimized with the model for a
patient in the training sample (0621c0014). The solid
curve represents the clinical treatment plan and the
dashed curve represents the re-optimized treatment
plan.
4.2 Validation and Plan Optimization
After the model was trained it was validated and
tested as a tool for improving plan quality on a
sample of 8 treatment plans selected from outside
the training sample. The EDVH bands and model
generated optimization objectives were used to at-
tempt to reduce dose to the OARs while maintaining
target coverage and minimizing dose heterogeneity
within the target as much as possible.
Validation was carried out to ensure that the
model accurately predicts EDVH bands for all
geometries included in its training sample. To do
this re-optimized DVHs were compared with the
EDVH bands for all plans in the validation/testing
sample. Fig 3 shows an example validation plot for
patient 0621c0032 demonstrating that the DVHs for
the bladder-CTV2 and rectum fall within the EDVH
bands as expected. Validation plots for the full
validation/testing sample are shown in appendix B.
In the initial phase of treatment for all patients
in the validation sample the DVHs for the bladder-
CTV2 and rectum fall within the EDVH bands over
most of the dose range. In a few cases the DVHs fall
within the EDVH bands for most of the range and
just beyond the bands for part of the range. This
can be expected given that the bands represent a
one standard deviation variation from the average
DVH predicted by the model. The model for the
initial phase is well validated.
For the CD phase there are some discrepancies
between the DVHs and EDVH bands arising from
patients in the validation sample that are geomet-
ric outliers with respect to the training sample.
The most dramatic example of this is for patient
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0621c0031 for which both the target volume and
target/rectum overlap are significantly larger than
the mean values in the training sample. This causes
the model to make an unrealistic prediction for the
rectum DVH. Patient 0621c0016 also shows a signif-
icant discrepancy between the DVH and the EDVH
band for the bladder-CTV2. For patients 0621c0016
and 0621c0032 the EDVHs for the bladder-CTV2
become quit narrow in the high dose range showing a
sharp kink near the full prescription dose of the CD
phase. These patients were identified by RapidPlan
as outliers of the model. For 0621c0016 the target of
the CD phase (PTV2) is too large with respect to
the patients in the training sample for the model to
make an accurate prediction. Similarly for 0621c0032
the overlap region between the bladder-CTV2 and
PTV2 is too large. These outlier geometric features
account for the narrow EDVH bands for these
patients. There are few patients corresponding to
their geometry in the training sample and so the
model is overtrained for those geometries. In the
case of patient 0621c0016 this leads to a significant
discrepancy between the DVH and EDVH band near
the kink. With these exceptions the model for the
CD phase is well validated by the remaining patients
in the validation/testing sample.
In addition to validation the model was tested as
a planning QA tool by comparing the re-optimized
treatment plans to the original clinical treatment
plans submitted to the trial. A comparison of DVHs
before and after re-optimization with the model is
shown in Fig 4 for patient 0621c0039. The plot
shows a significant improvement of OAR sparing
for both the rectum and bladder-CTV2 without
sacrificing target coverage. For the bladder-CTV2
V50Gy is reduced from 47.17 % to 32.82 % and
V66.6Gy is reduced from 14.20 % to 6.32 %. For
the rectum V50Gy is reduced from 23.64 % to 13.09
% and V66.6Gy is reduced from % 3.38 to 0.49
%. Dose heterogeneity within the target (Dhet) is
increased from 6.61 % to 15.47 %. Of the 8 patients
in the validation/testing sample 5 were able to be
re-optimized with the model to achieve greater OAR
sparing without excessive degradation of Dhet. For
the remaining 3 patients the treatment plans were
not able to be optimized beyond the clinical plans
submitted to the trial.
Similar comparison plots for these re-optimized
plans are shown in appendix C. Table 6 in
appendix D gives the values of V50Gy, V66.6Gy
and Dhet for these patients before and after re-
optimization with the model. The integral dose to
the bladder-CTV2 and rectum as well as V50Gy and
V66.6Gy for the bladder-CTV2 and V50Gy for the
rectum are reduced for all 5 plans. V66.6Gy for the
rectum is reduced in 2 plans and increased in 3 plans.
Figure 3: Plot showing overlay of DVHs with esti-
mated DVH bands predicted by the RapidPlan model
for the bladder-CTV2 (green), rectum (magenta) and
PTV1 (red). The plot shown is for patient 0621c0032
in the validation/testing sample
Figure 4: Dose volume histogram (DVHs) showing
a comparison of the clinical treatment plan with the
treatment plan re-optimized with the model for pa-
tient 0621c0032 in the validation/testing sample. The
solid curve represents the clinical treatment plan and
the dashed curve represents the re-optimized treat-
ment plan. DVH Comparison plots for the full vali-
dation/testing sample are shown in appendix C.
4.2.1 Biological Effect of Optimization
A summary of the results of the radiobiological anal-
ysis described in section 3.3.1 is shown in table 5.
The table shows average values of a number of im-
portant radiobiological parameters for the treatment
plans in the validation/testing sample before and
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after re-optimization with the model. These include
V50Gy, V66.6Gy, EUD, NTCP for the rectum and
bladder-CTV2 and TCP for the prostate bed. The
average reduction in V50Gy and V66.6Gy for the
bladder-CTV2 was 14.29 ± 9.14 % and 6.68 ± 6.94
%. The average reduction in V50Gy for the rectum
was 9.89 ± 7.62 % while V66.6Gy actually increased
by 0.5 ± 4.76 %. The average reduction in NTCP
was 0.34 ± 0.21 % for the bladder-CTV2 and 0.11 ±
0.25 % for the rectum with corresponding p-values of
0.116 and 0.668. The average TCP for the prostate
bed decreased slightly from 97.05 % to 96.54 % with
a p-value of 0.149. Due to limited statistics in the
validation/testing sample the changes reported in
these numbers are not statistically significant. The
error bars overlap significantly and the p-values
are too large to reject the null hypothesis that
re-optimization with the model has no effect on
overall plan quality on average.
However, although the average values are incon-
clusive the model was effectively used to identify
individual treatment plans that were sub-optimal
and improve their quality through re-optimization.
The results of the radiobiological analysis for each of
the 5 re-optimized plans are shown in appendix D.
For patient 0621c0027 the NTCP decreased from
0.35 % to 0.06 % for the bladder-CTV2 and from
0.10 % to 0.06 % for the rectum while the TCP
increased from 96.78 % to 96.87 %.
Table 5: Summary of mean and standard deviation
for dose volume parameters, equivalent uniform dose
(EUD), tumor control probabilities (TCP) for the
PTV and normal tissue complication probabilities
(NTCP) for the bladder-CTV2 and rectum before
and after re-optimization. The values are given for
each individual treatment plan in the appendix D
5 Conclusion
A KBP model was developed with RapidPlan for the
treatment of high risk post-prostatectomy prostate
cancer with IMRT. The model was trained on a sam-
ple of 39 treatment plans submitted to the national
clinical trial RTOG 0621 with IROC scores of 1 or 2
indicating good adherence to the trial compliance cri-
teria. The model was optimized through an iterative
process of re-optimizing plans in the training sample
and retraining. It was then validated and tested on
a sample of 8 treatment plans selected from outside
the training sample. The model was shown to ac-
curately predict estimated DVH bands for all plans
in the validation sample excluding geometric outliers.
The model was tested as a planning QA tool by us-
ing it to re-optimize plans outside the training sam-
ple and doing a radiobiological comparison of the re-
optimized plans and the clinical plans submitted to
the trial.
Five treatment plans were re-optimized with the
model showing significant increase in dose sparing for
the bladder-CTV2 and rectum with some increase in
dose heterogeneity within the target. The determi-
nation of whether overall plan quality was improved
in these cases ultimately depends on patient specific
details as well as the experience and judgement of
the treating physician. On average the NTCP for
the bladder-CTV2 and rectum decreased for both
OARs while the TCP for the prostate bed increased
slightly, however these changes were not statistically
significant given the limited statistics in the study.
Nonetheless the model was successfully used to iden-
tify sub-optimal plans and improve their quality sug-
gesting that it may be an effective tool for planning
QA for the treatment of prostate cancer with IMRT.
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Appendicies
A Re-optimization of Treatment Plans in Training Sample
Figure 5: Dose volume histogram (DVHs) showing a comparison of the initial phase of the clinical and
re-optimized treatment plans for patients 09, 11, 14, 15, 18 and 19 in the training sample. The solid curve
represents the clinical treatment plan and the dashed curve represents the re-optimized treatment plan.
The plots show significant improvement of OAR sparing for both the rectum and bladder-CTV2 without
sacrificing target coverage. The clinical plans were replaced in the training sample by these re-optimized
plans to improve the quality of the model.
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Figure 6: Dose volume histogram (DVHs) showing a comparison of the initial phase of the clinical and
re-optimized treatment plans for patients 09, 11, 14, 15, 18 and 19 in the training sample. The solid curve
represents the clinical treatment plan and the dashed curve represents the re-optimized treatment plan.
The plots show significant improvement of OAR sparing for both the rectum and bladder-CTV2 without
sacrificing target coverage. The clinical plans were replaced in the training sample by these re-optimized
plans to improve the quality of the model.
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Figure 7: Dose volume histogram (DVHs) showing a comparison of the initial phase of the clinical and
re-optimized treatment plan for patients in the training sample. The solid curve represents the clinical
treatment plan and the dashed curve represents the re-optimized treatment plan. The plots show significant
improvement of OAR sparing for both the rectum and bladder-CTV2 without sacrificing target coverage.
The clinical plans were replaced in the training sample by these re-optimized plans to improve the quality
of the model.
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Figure 8: Dose volume histogram (DVHs) showing a comparison of the initial phase of the clinical treatment
plan with the treatment plan re-optimized with the model for patients 71 and 76 in the training sample.
The solid curve represents the clinical treatment plan and the dashed curve represents the re-optimized
treatment plan. The plots show significant improvement of OAR sparing for both the rectum and bladder-
CTV2 without sacrificing target coverage.
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Figure 9: Dose volume histogram (DVHs) showing a comparison of the CD phase of the clinical and re-
optimized treatment plan for patients 18, 24, 52 and 59 in the training sample. The solid curve represents
the clinical treatment plan and the dashed curve represents the re-optimized treatment plan. The plots show
significant improvement of OAR sparing for both the rectum and bladder-CTV2 without sacrificing target
coverage.
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B Model Validation
Figure 10: Plots showing overlay of DVHs with estimated DVH bands predicted by the RapidPlan model for
the bladder-CTV2 (green) and Rectum (magenta) and PTV1 (red) in the initial phase of treatment. The
plots shown are for the treatment plans in the validation/testing sample which includes patients 16, 27, 31
and 32 (reading left to right from top left to bottom right).
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Figure 11: Plots showing overlay of DVHs with estimated DVH bands predicted by the RapidPlan model for
the bladder-CTV2 (green) and rectum (magenta) and PTV2 (orange) in the CD phase of treatment. The
plots shown are for patients 33, 39, 43 and 80 (reading left to right from top left to bottom right)
16
C Re-optimization of Treatment Plans in Validation/Testing sam-
ple
Figure 12: Dose volume histogram (DVHs) showing a comparison of the clinical treatment plan with the
treatment plan re-optimized with the model for patients 27, 32, 39, 43 and 80 in the validation/testing
sample. The solid curve represents the clinical treatment plan and the dashed curve represents the re-
optimized treatment plan. The plots show significant improvement of OAR sparing for both the rectum and
bladder-CTV2 without sacrificing target coverage.
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D Results of Radiobiological Analysis
Table 6: Summary of dose volume parameters, tumor control probabilities (TCP) for the prostate bed and
normal tissue complication probabilities (NTCP) for the bladder-CTV2 and rectum before and after re-
optimization for each plan in the validation/testing sample. In most cases V50Gy, V66.6Gy, EUD and NTCP
for the bladder-CTV2 and rectum are reduced by re-optimization.
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